148 related articles for article (PubMed ID: 1063029)
1. Cell-mediated cytotoxicity as a result of immunotherapy in patients with acute myeloid leukaemia.
Taylor GM; Harris R; Freeman CB
Br J Cancer; 1976 Feb; 33(2):137-43. PubMed ID: 1063029
[TBL] [Abstract][Full Text] [Related]
2. Proceedings: Cell mediated cytotoxicity (CMC) in patients with acute myeloblastic leukaemia receiving immunotherapy.
Taylor GM; Harris R; Freeman CB
Br J Cancer; 1975 Aug; 32(2):242. PubMed ID: 1061614
[No Abstract] [Full Text] [Related]
3. Generation of T-cell lines to autologous acute myeloid leukemia cells by competitive limiting dilution culture of acute myeloid leukemia mononuclear cells.
Zhong RK; Lane TA; Ball ED
Exp Hematol; 2008 Apr; 36(4):486-94. PubMed ID: 18249062
[TBL] [Abstract][Full Text] [Related]
4. Cellular sensitization in chronic myeloid leukaemia patients to leukaemic blast antigens.
Gangal SG; Damle NK; Khare AG; Advani SH
Br J Cancer; 1979 Sep; 40(3):391-6. PubMed ID: 292450
[TBL] [Abstract][Full Text] [Related]
5. The CD226-ERK1/2-LAMP1 pathway is an important mechanism for Vγ9Vδ2 T cell cytotoxicity against chemotherapy-resistant acute myeloid leukemia blasts and leukemia stem cells.
Wu K; Wang LM; Liu M; Xiu Y; Hu Y; Fu S; Huang H; Xu B; Xiao H
Cancer Sci; 2021 Aug; 112(8):3233-3242. PubMed ID: 34107135
[TBL] [Abstract][Full Text] [Related]
6. Induction of cytotoxic lymphocyte subsets against leukemia by stimulation with AML blasts.
Lotzová E; Savary CA
Med Oncol Tumor Pharmacother; 1993; 10(1-2):13-9. PubMed ID: 8258990
[TBL] [Abstract][Full Text] [Related]
7. The role of allogeneic cells in the stimulation of cell-mediated cytotoxicity to leukaemia cells. A family study.
Taylor GM; Bradley BA
Cancer Immunol Immunother; 1983; 15(1):39-46. PubMed ID: 6553506
[TBL] [Abstract][Full Text] [Related]
8. Biological treatment in acute myelogenous leukaemia: how should T-cell targeting immunotherapy be combined with intensive chemotherapy?
Bruserud Ø; Wendelboe Ø
Expert Opin Biol Ther; 2001 Nov; 1(6):1005-16. PubMed ID: 11728232
[TBL] [Abstract][Full Text] [Related]
9. Receptors for human immunoglobulin on acute myeloid leukaemic leucocytes.
Ridway JC; Taylor GM; Freeman CB; Harris R
Br J Cancer; 1976 Oct; 34(4):346-58. PubMed ID: 823953
[TBL] [Abstract][Full Text] [Related]
10. Gene transfer to primary acute myeloid leukaemia blasts and myeloid leukaemia cell lines.
Roddie PH; Paterson T; Turner ML
Cytokines Cell Mol Ther; 2000 Sep; 6(3):127-34. PubMed ID: 11140881
[TBL] [Abstract][Full Text] [Related]
11. Further evidence of response by leukaemia patients in remission to antigen(s) related to acute myelogenous leukaemia.
Cocks P; Powles RL; Chapuis B; Alexander P
Br J Cancer; 1977 Mar; 35(3):273-9. PubMed ID: 139910
[TBL] [Abstract][Full Text] [Related]
12. Restoration of the LFA-3 adhesion pathway in Burkitt's lymphoma cells using an LFA-3 recombinant vaccinia virus: consequences for T cell recognition.
Griffin H; Rowe M; Murray R; Brooks J; Rickinson A
Eur J Immunol; 1992 Jul; 22(7):1741-8. PubMed ID: 1378014
[TBL] [Abstract][Full Text] [Related]
13. In vitro stimulation of cell-mediated cytotoxicity by acute leukaemias.
Taylor GM
Br J Cancer; 1981 Feb; 43(2):157-68. PubMed ID: 6451236
[TBL] [Abstract][Full Text] [Related]
14. HLA-DPB1 mismatch alleles represent powerful leukemia rejection antigens in CD4 T-cell immunotherapy after allogeneic stem-cell transplantation.
Herr W; Eichinger Y; Beshay J; Bloetz A; Vatter S; Mirbeth C; Distler E; Hartwig UF; Thomas S
Leukemia; 2017 Feb; 31(2):434-445. PubMed ID: 27479183
[TBL] [Abstract][Full Text] [Related]
15. Detection of an antigen associated with acute leukemia.
Mann DL; Rogentine GN; Halterman R; Leventhal B
Science; 1971 Dec; 174(4014):1136-7. PubMed ID: 5289583
[TBL] [Abstract][Full Text] [Related]
16. [Biological properties and sensitivity to induction therapy of differentiated cells expressing atypical immunophenotype in acute leukemia of children].
Pituch-Noworolska A
Folia Med Cracov; 2001; 42(3):5-80. PubMed ID: 12353422
[TBL] [Abstract][Full Text] [Related]
17. Cytokine Release Patterns in Mixed Lymphocyte Culture (MLC) of T-Cells with Dendritic Cells (DC) Generated from AML Blasts Contribute to Predict anti-Leukaemic T-Cell Reactions and Patients' Response to Immunotherapy.
Fischbacher D; Merle M; Liepert A; Grabrucker C; Kroell T; Kremser A; Dreyßig J; Freudenreich M; Schuster F; Borkhardt A; Kraemer D; Koehne CH; Kolb HJ; Schmid C; Schmetzer HM
Cell Commun Adhes; 2015; 22(2-6):49-65. PubMed ID: 27602789
[TBL] [Abstract][Full Text] [Related]
18. Inability to demonstrate lytic antibodies to autologous leukaemia cells in the sera from remission patients with acute myelogenous leukaemia treated with active specific immunotherapy.
Chapuis BJ; Powles R; Alexander P
Clin Exp Immunol; 1978 May; 32(2):253-8. PubMed ID: 276431
[TBL] [Abstract][Full Text] [Related]
19. Cell-mediated destruction of human leukemic cells by MHC identical lymphocytes: requirement for a proliferative trigger in vitro.
Sondel PM; O'Brien C; Porter L; Schlossman SF; Chess L
J Immunol; 1976 Dec; 117(6):2197-203. PubMed ID: 1069027
[TBL] [Abstract][Full Text] [Related]
20. Specificity of heteroantisera to human acute leukemia-associated antigens.
Baker MA; Ramachandar K; Taub RN
J Clin Invest; 1974 Dec; 54(6):1273-8. PubMed ID: 4140196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
